AGEN: Agenus, Inc. Analyst Target Range
This daily price chart for Agenus (AGEN) reflects the dynamics of a company generating revenue from antibody licensing and payments from major partners. The business relies on building an oncology portfolio through a proprietary molecule discovery system designed to combat tumors. The current consensus is 24.99. Despite regulatory challenges, the brand's scientific authority ensures sustained interest in its innovations.
Analytical breakdowns for Agenus Inc (AGEN)
- stock value and consensus price forecast:
- market capitalization information:
- book capitalization data:
- debt obligations and liquidity statistics:
Aggregate Debt to Equity Agenus|AGEN - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Agenus, Inc|AGEN - Company Aggregate Debts|Debts to Book Capitalization Agenus Inc|AGEN - Company Long-Term Debt|Company Short-Term Loans and Borrowings Agenus|Quick Liquidity Indicator agenusbio.com
- earnings and multiples data:
AGEN - Net Profit|Projected Future Earnings Agenus|AGEN - Price to Earnings Ratio|Future Price to Earnings Multiple Agenus, Inc.|AGEN - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Agenus Inc|AGEN - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Agenus|AGEN - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months agenusbio.com|AGEN - Net earnings per share growth this year|Earnings growth forecast for next year Agenus
General company analysis:AGEN agenusbio.com
The asset's calculated value is based on the discounting of future cash flows adjusted for macroeconomic rates, consolidating expert fair value estimates into a single benchmark. For Agenus (AGEN), which is currently finalizing key clinical trials for immunotherapy, the current consensus valuation reflects market expectations regarding the success of regulatory approvals and the subsequent commercialization of its drugs.
Competitors of Agenus
Analyst Consensus Forecast argenx.com (ARGX)|Analyst Consensus Forecast BNTX (BioNTech)|Analyst Target Range Abivax SA|ADMA Bio - Analyst Consensus Forecast|Average Forecast Price Protagonist Corp|Immunovant, Inc. (IMVT) - Price Target Chart|Broker Consensus Forecast KNSA|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|Aerovate - Analyst Consensus Forecast|ACRS - Analyst Consensus Forecast|KYTX: Analyst Consensus Forecast|Analyst Target Range tizianalifesciences.com TLSA|CABA (Cabaletta Bio) - Analyst Consensus Forecast|Average Forecast Price Ventyx Biosciences Inc. VTYX|Price Target Chart Theratechnologies Inc (THTX)|Avalo Therapeutics Inc - Broker Consensus Forecast|Eledon Pharmaceuticals - Consensus Target|Analyst Consensus Forecast climbbio.com CLYM|ZURA - Price Target Chart|Analyst Median Target aTyr Pharma Inc ATYR|ADAG: Analyst Consensus Forecast|Ikena Oncology (IMA) - Analyst Consensus Forecast|STTK (Shattuck Labs Inc) - Analyst Consensus Forecast|EQ - Analyst Target Range|Analyst Consensus Forecast CNTB|IMUX - Average Forecast Price|Price Target Chart Atara Bio ATRA|IFRX: Broker Consensus Forecast|XFOR - Price Target Chart|Forecast Levels Chart ACET|CELU: Analyst Consensus Forecast|INmune Bio Inc - Fair Value Consensus|BRNS (Barinthus Bio) - Analyst Consensus Forecast|Analyst Consensus Forecast Kezar Life Sciences Inc|Price Target Chart SAB Biotherapeutics (SABS)|AKTX (akaritx.com) - Fair Value Consensus|Price Target Chart Enlivex Therapeutics Ltd. ENLV|QTTB - Consensus Target|GeoVax Labs Inc - Analyst Consensus Forecast|EDSA - Analyst Consensus Forecast|IBIO (iBio, Inc.) - Consensus Target|Carisma Therapeutics Inc. - Fair Value Consensus|XTLB (XTL Biopharmaceuticals Ltd.) - Analyst Consensus Forecast|Bolt Bio (BOLT) - Analyst Median Target|Price Target Chart HCW Biologics Inc. (HCWB)|Consensus Target aptevotherapeutics.com APVO|Price Target Chart AIM ImmunoTech AIM|ADTX - Consensus Target|GRI: Consensus Target|XRTX - Analyst Consensus Forecast|ReShape Lifesciences (HIND) - Price Target Chart|Broker Consensus Forecast REVB|INDP (Indaptus Therapeutics) - Analyst Consensus Forecast|Average Forecast Price scinai.com SCNI|Analyst Consensus Forecast CALI|Analyst Consensus Forecast affimed.com (AFMD)|Analyst Consensus Forecast ALLK (Allakos)|Analyst Target Range HOOKIPA Pharma, Inc.|IGM Bio - Analyst Consensus Forecast|Average Forecast Price iteostherapeutics.com|Ocean Biomedical (OCEA) - Price Target Chart|Broker Consensus Forecast TCBP|Consensus Target THRD
